COST-EFFECTIVENESS ANALYSIS OF ADDING PIOGLITAZONE TO INSULIN REGIMEN IN TYPE2 DIABETES IN IRAN

被引：0
|
作者：
Davari, M. [1 ]
Khorasani, E. [1 ]
Shojaei, Savari R. [1 ]
Sari, Akbari A. [2 ]
Saiyarsarai, P. [3 ]
机构：
[1] Univ Tehran Med Sci, Tehran, Iran
[2] Univ Tehran Med Sci, Sch Publ Hlth, Tehran, Iran
[3] Univ Tehran Med Sci, Dept Pharmacoecon & Pharmaceut Management, Fac Pharm, Tehran, Iran
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.774
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB69
引用
收藏
页码：S129 / S130
页数：3
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS ANALYSIS OF INSULIN DEGLUDEC/INSULIN ASPART VERSUS INSULIN GLARGINE IN PATIENTS WITH TYPE 2 DIABETES IN CHINA
    Liu, C.
    Tao, L. B.
    Wang, F.
    VALUE IN HEALTH, 2020, 23 : S111 - S111
  • [22] COST-EFFECTIVENESS ANALYSIS OF INSULIN DEGLUDEC/INSULIN ASPART VERSUS INSULIN GLARGINE IN PATIENTS WITH TYPE 2 DIABETES IN CHINA
    Xu, J.
    Lan, K.
    Wang, J.
    VALUE IN HEALTH, 2020, 23 : S111 - S111
  • [23] A cost-effectiveness analysis of linagliptin add-on to insulin treatment for patients with type 2 diabetes mellitus and chronic kidney disease in Iran
    Soroush Ahmadi Fariman
    Marzieh Nosrati
    Parham Rahmani
    Shekoufeh Nikfar
    Journal of Diabetes & Metabolic Disorders, 2023, 22 : 1263 - 1271
  • [24] A cost-effectiveness analysis of linagliptin add-on to insulin treatment for patients with type 2 diabetes mellitus and chronic kidney disease in Iran
    Fariman, Soroush Ahmadi
    Nosrati, Marzieh
    Rahmani, Parham
    Nikfar, Shekoufeh
    JOURNAL OF DIABETES AND METABOLIC DISORDERS, 2023, 22 (02) : 1263 - 1271
  • [25] COST-EFFECTIVENESS ANALYSIS OF BIPHASIC INSULIN ASPART VERSUS INSULIN GLARGINE IN PEOPLE WITH TYPE 2 DIABETES IN CHINA
    Xu, Z.
    Han, P.
    Wei, Y.
    Zhang, Y.
    Wu, J.
    VALUE IN HEALTH, 2014, 17 (03) : A247 - A247
  • [26] Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation
    Czoski-Murray, C
    Warren, E
    Chilcott, J
    Beverley, C
    Psyllaki, MA
    Cowan, J
    HEALTH TECHNOLOGY ASSESSMENT, 2004, 8 (13) : 1 - +
  • [27] COMPARATIVE COST-EFFECTIVENESS ANALYSIS OF ADDING TWICE-DAILY EXENATIDE TO INSULIN GLARGINE VERSUS ADING INSULIN LISPRO TO TREAT TYPE 2 DIABETES IN SPAIN
    Sanchez-Covisa, J.
    Capel, M.
    Baeten, S.
    Verheggen, B. G.
    VALUE IN HEALTH, 2014, 17 (07) : A349 - A349
  • [28] The cost-effectiveness of insulin analogs and regular insulin for diabetes control: a case study in Iran
    Pakdaman, Mohsen
    Akbari, Raheleh
    Dehghan, Hamid Reza
    Asgharzadeh, Asra
    Namayandeh, Mahdieh
    INTERNATIONAL JOURNAL OF HEALTH CARE QUALITY ASSURANCE, 2020, 33 (4-5) : 323 - 331
  • [29] Cost-Effectiveness of Insulin Glargine and Insulin Detemir in the Basal Regimen for Naive Insulin Patients with Type 2 Diabetes Mellitus (T2DM) in Malaysia
    Shafie, Asrul Akmal
    Ng, Chin Hui
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2020, 12 : 333 - 343
  • [30] COST-EFFECTIVENESS ANALYSIS OF IGLARLIXI COMPARED WITH BASAL BOLUS INSULIN REGIMEN IN TRIPLE METABOLIC GOAL IN TYPE 2 DIABETES MELLITUS IN LATIN AMERICA
    Londono, S.
    Garcia, W.
    Salamanca, C.
    Silva, L.
    Santos, V
    Upegui, A.
    VALUE IN HEALTH, 2023, 26 (12) : S172 - S172
12345